1. Introduction {#s0005}
===============

Though epithelial ovarian cancer (EOC) is rare, across the globe, over 200,000 new cases of ovarian cancer are diagnosed yearly \[[@bb0005]\]. Because the majority of diagnoses are advanced-stage disease with poor prognosis and cancer recurrence after treatment \[[@bb0010],[@bb0015]\], globally, over 150,000 women die from this cancer each year \[[@bb0020]\]. Aside from family history of breast or ovarian cancer, high body mass index in adolescence, diagnosis of endometriosis, and taller height, most established risk factors are hormonal or reproductive \[[@bb0005]\]. A recent Mendelian randomization (MR) study of 13 known observational risk factors only confirmed genetic liability to lifetime smoking and endometriosis as causal \[[@bb0025]\]. Thus, identification of additional risk factors is crucial for designing prevention strategies and for earlier diagnosis of EOC.

Because EOC and breast cancer share many similar risk factors and schizophrenia (SZ) has been reported to be a causal risk factor for breast cancer in a recent Mendelian randomization (MR) study \[[@bb0030]\], we hypothesized that SZ or something about its disease pathogenesis, perhaps metabolic, may be a risk factor for EOC. One possibility is energy metabolism, as it is important in both cancer \[[@bb0035]\] and schizophrenia (SZ) \[[@bb0040],[@bb0045]\]. In particular, aberrant choline metabolism has been documented for EOC \[[@bb0050],[@bb0055]\] and also noted in the brains of schizophrenics \[[@bb0040]\]. We conducted an MR study of SZ and EOC and its subtypes, and, to assess whether EOC might influence SZ, we also tested the reverse: the causal impact of EOC on SZ. As proof of principle that SZ may impact on circulating metabolites that have been associated with EOC, we performed MR of SZ on 15 circulating 1- or 2-glycerophosphocholine (1- or 2-GPC) metabolites.

2. Materials and methods {#s0010}
========================

2.1. Conceptual framework {#s0015}
-------------------------

MR is an instrumental-variables technique that exploits the random assortment of alleles, using, most commonly, single-nucleotide polymorphisms (SNPs) as instruments ("proxies") \[[@bb0060],[@bb0065]\]. With summary results from genome-wide association studies (GWASs), we used two-sample MR to test the causal relationships between 1) EOC and SZ and 2) SZ and 1- or 2-GPC species. We presumed the following assumptions: the chosen instrumental variables (SNPs) are strongly associated with exposures (assumption 1); the instrumental variables are not associated with confounders (assumption 2); and the instrumental variables are only associated with the outcomes through the exposures (assumption 3) \[[@bb0070]\].

2.2. Data sources {#s0020}
-----------------

Two-sample MR uses the summary results from two separate GWASs as its data sources: a GWAS of the exposure and a GWAS of the outcome.

### 2.2.1. SZ on EOC and EOC subtypes {#s0025}

1)We selected a GWAS of SZ \[[@bb0075]\]; Ripke et al. (2014) meta-analyzed 49 case-control studies of SZ along with 1235 parent affected-offspring trios (total study size = 35,476 SZ cases and 46,839 controls). From their GWAS results, we extracted the summary statistics for SNPs strongly associated with SZ (*p*-value \<5e-8).2)Next, we identified the largest GWAS of EOC and its subtypes \[[@bb0080]\]; Phelan et al. (2017) meta-analyzed GWAS from six Ovarian Cancer Association Consortium (OCAC) and two Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) projects (total study size = 25,509 cases and 40,941 controls of European ancestry) for women who had been genotyped using the Illumina Custom Infinium array (OncoArray). We extracted summary data for the SZ-associated SNPs from within the GWAS of overall EOC (*n* = 25,509), high-grade serous carcinoma (*n* = 13,037), mucinous carcinoma (*n* = 2566), endometrioid carcinoma (*n* = 2810), and clear-cell carcinoma (*n* = 1366).

### 2.2.2. EOC on SZ (reverse direction) {#s0030}

For the MR of EOC on SZ, we selected SNPs strongly associated with EOC (*p*-value \<5e-8) from the Phelan et al. \[[@bb0080]\] GWAS of EOC.

We extracted the summary data for the EOC-associated SNPs from the Ripke et al. \[[@bb0075]\] GWAS of SZ.

### 2.2.3. SZ on 15 1- or 2-GPC species {#s0035}

For the MR of SZ on 1- or 2-GPC species, we extracted SZ-associated SNPs (*p*-value \<5e-8) from Ripke et al. \[[@bb0075]\].

We then selected GWASs of circulating metabolites in, depending on the metabolite, up to 7824 adult individuals from two European population studies (TwinsUK and the Cooperative Health Research in the Region of Augsburg (KORA) study) performed by Shin et al. (2014). We extracted summary statistics for SZ-associated SNPs for 15 1- or 2-GPC metabolites: 1-arachidonoylglycerophosphocholine, 1-palmitoleoylglycerophosphocholine, 1-eicosatrienoylglycerophosphocholine, 1-docosahexaenoylglycerophosphocholine, 1-eicosadienoylglycerophosphocholine, 1-palmitoylglycerophosphocholine, 1-heptadecanoylglycerophosphocholine, 1-oleoylglycerophosphocholine, 1-stearoylglycerophosphocholine, 1-linoleoylglycerophosphocholine, 2-palmitoylglycerophosphocholine, 2-oleoylglycerophosphocholine, 2-stearoylglycerophosphocholine, 2-linoleoylglycerophosphocholine, 1-myristoylglycerophosphocholine \[[@bb0085]\].

2.3. Statistical procedure {#s0040}
--------------------------

### 2.3.1. SZ on EOC and EOC subtypes {#s0045}

To implement MR for the tests of SZ on overall EOC and SZ on EOC subtypes, we used the summary statistics for SZ-associated SNPs identified in and extracted from Ripke et al. \[[@bb0075]\] and the summary statistics for the Ripke-SZ-associated SNPs extracted from Phelan et al. \[[@bb0080]\] to calculate the odds ratio (OR) for overall EOC and for each subtype per unit log odds higher liability to SZ for each SNP instrument (Wald ratio) and conducted a meta-analysis of the Wald ratios in a combined instrument with the inverse-weighted variance (IVW) MR method \[[@bb0090]\].

### 2.3.2. EOC on SZ {#s0050}

To implement MR for the test of EOC on SZ, we used the summary statistics for EOC-associated SNPs identified in and extracted from Phelan et al. \[[@bb0080]\] and the summary statistics for the Phelan-EOC-associated SNPs extracted from Ripke et al. \[[@bb0075]\] to calculate the odds ratio (OR) for SZ per unit log odds higher liability to EOC for each SNP instrument (Wald ratio) and meta-analyzed the results with the IVW method. The MR of SZ on EOC and the reverse MR of EOC on SZ comprise a bidirectional analysis. Because the validity of bidirectional MR methods depends on the independence of the two instruments \[[@bb0060]\], we checked that there was no overlap or linkage disequilibrium (LD) between the genetic variants included in the instruments for SZ and EOC. We used LDassoc, a free and publicly available web tool, to assess whether instruments were in LD \[[@bb0095]\].

### 2.3.3. SZ on 15 1- or 2-GPC species {#s0055}

To implement MR for the tests of SZ on 15 1- OR 2-GPC metabolites, we used the summary statistics for the SZ-associated SNPs identified in and extracted from Ripke et al. \[[@bb0075]\] and Ripke-SZ-associated SNPs extracted from the Shin et al. \[[@bb0085]\] GWAS of circulating 1- or 2-GPC metabolites. We calculated the log10 increase in 1- or 2-GPC metabolite per unit log odds higher liability to SZ for each SNP proxy and meta-analyzed the Wald ratios with the IVW method. We performed 15 meta-analyses, one for each of the 15 1- or 2-GPC metabolites. To account for multiple testing, we set the *P*-value threshold for the analyses of SZ on 1- or 2-GPCs to the Bonferroni-corrected value of 0.0033 (*P* = .05/15).

2.4. Two-sample MR {#s0060}
------------------

For all instruments, where the exposure SNPs were not available in the outcome data, we identified LD proxy SNPs in linkage disequilibrium (R^2^ \> 0.8 and within 250 kb of the target SNP). We implemented all two-sample MR tests in R version 3.5.1 using the "TwoSampleMR" package \[[@bb0100]\]. All data are publicly available and accessible through the MR-Base website, a curated database of complete GWASs and platform for performing two-sample MR \[[@bb0105]\].

2.5. Sensitivity analyses {#s0065}
-------------------------

To detect possible violations of the third MR assumption (assumption 3 above), we performed various sensitivity analyses. We applied IVW radial regression for each MR test. IVW radial regression uses the *P*-value from Cochran\'s *Q*-statistic (*P*\[het\]) to identify possible heterogeneity among an instrument\'s ratio estimates \[[@bb0110]\]. Heterogeneity can indicate pleiotropy. For all analyses, we removed heterogenous SNPs and report the results of the MR analysis with them removed, along with IVW radial regression performed again after their removal to demonstrate either absence of evidence for heterogeneity or continued evidence for it. The tables of results include the number of SNPs included in each analysis. We also implemented MR-Egger regression, weighted median, and weighted mode estimators, which make different assumptions about the underlying nature of potential pleiotropy. Briefly, if the MR-Egger, weighted median, and weighted mode estimators have the same direction and comparable magnitude of effects as the IVW estimate, this strengthens confidence in the validity of the instruments.

3. Results {#s0070}
==========

3.1. SZ and EOC {#s0075}
---------------

SZ was associated with overall EOC (IVW OR per log odds higher liability to SZ: 1.09, 95% CI: 1.04, 1.14; *P* = .0004) and high-grade serous ovarian carcinoma (IVW OR 1.07, 95% CI: 1.01, 1.13; *P* = .033). The comparisons of the MR estimators for both reveal little evidence for pleiotropy: the direction of the effect was consistent across methods and the effects were of relatively the same magnitude for the IVW, weighted median, and weighted mode estimators ([Table 1](#t0005){ref-type="table"}; [Fig. 1](#f0005){ref-type="fig"}). IVW radial regression indicated no evidence of heterogeneity (overall EOC: *P*\[het\] = 0.5238; high-grade serous: *P*\[het\] = 0.4254).Table 1MR of SZ on overall EOC and four ovarian cancer subtypes.Table 1MethodNLowerUpper*P-Value*SNPsOR95% CI95% CIOverall EOCInverse variance weighted661.091.041.140.0004MR Egger661.181.001.390.0600MR Egger intercept660.990.981.010.3345Weighted median661.101.031.180.0077Weighted mode661.080.911.270.3778High grade serousInverse variance weighted621.071.011.130.0333MR Egger621.080.851.350.5386MR Egger intercept621.000.981.020.9344Weighted median621.050.971.140.2171Weighted mode621.060.861.300.5857MucinousInverse variance weighted651.090.981.210.1258MR Egger regression651.220.841.770.3027MR Egger intercept650.990.961.020.5282Weighted median651.171.001.360.0510Weighted mode651.360.971.910.0797EndometriodInverse variance weighted641.100.991.220.0804MR Egger regression641.330.881.990.1778MR Egger intercept640.980.951.020.3478Weighted median641.140.991.320.0753Weighted mode641.230.871.740.2503Clear cellInverse variance weighted651.060.921.220.4227MR Egger651.180.672.070.5622MR Egger intercept650.990.951.040.6968Weighted median651.150.941.400.1780Weighted mode651.210.771.910.4083Fig. 1MR results of genetic liability to SZ on overall EOC and four EOC subtypes.Fig. 1

Null, increased risks were observed for the remaining subtypes, and IVW radial regression revealed no evidence for heterogeneity: mucinous carcinoma (IVW OR 1.09; 95% CI 0.98, 1.21; *P* = .1258; *P*\[het\] = 0.7236); endometrioid carcinoma (OR 1.10; 95% CI 0.99, 1.22; *P* = .0804; *P*\[het\] = 0.9568); and clear-cell carcinoma (OR 1.06; 95% CI 0.92, 1.22; *P* = .4227; *P*\[het\] = 0.8990). The sensitivity estimators were relatively consistent for all tests (same direction of effect and comparable magnitudes of effect).

3.2. EOC on SZ {#s0080}
--------------

Genetic liability to EOC did not causally contribute to risk for SZ ([Table 2](#t0010){ref-type="table"}).Table 2Results of MR of EOC on SZ.Table 2MethodNLowerUpper*P-Value*SNPsOR95% CI95% CIOverall EOCInverse variance weighted90.950.871.040.2586MR Egger90.970.771.220.8220MR Egger intercept90.990.981.010.3345Weighted median90.940.861.030.2075Weighted mode90.950.841.060.3791

3.3. SZ on 1- or 2-GPC species {#s0085}
------------------------------

Two of the 15 tests of SZ on circulating 1- or 2-GPC species showed evidence for causal association and 3 had suggestive associations ([Table 3](#t0015){ref-type="table"}). SZ was associated with 1-palmitoleoylglycerophosphocholine (IVW beta log10 increase per log odds higher liability to SZ: -0.021, 95% CI: −0.032, −0.009; *P* = .0003; *P*\[het\] = 0.7337). Similarly, SZ was associated with 1-oleoylglycerophosphocholine (IVW beta: -0.017, 95% CI: −0.027, −0.007; *P* = .0006; *P*\[het\] = 0.8507). Suggestive associations were observed for 1-heptadecanoylglycerophosphocholine (IVW beta: -0.019, 95% CI: −0.033, −0.005; *P* = .0066; *P*\[het\] = 0.8664); 2-oleoylglycerophosphocholine (IVW beta: -0.014, 95% CI: −0.024, −0.004; *P* = .0074; *P*\[het\] = 0.8664); and1-myristoylglycerophosphocholine (IVW beta: -0.018, 95% CI: −0.031, −0.005; *P* = .0066; *P*\[het\] = 0.9419). The comparison of the MR estimators showed little evidence for pleiotropy for the 1- or 2-GPC metabolites after Bonferroni correction. The suggestively associated 1- or 2-GPC metabolites were also robust to the MR sensitivity analyses, except for 1-heptadecanoylglycerophosphocholine for which there was some discrepancy in the direction of effects for the MR estimators, indicating potential pleiotropy. For all the 1- or 2-GPCs, including the 10 that had null associations, SZ ([Fig. 2](#f0010){ref-type="fig"}) lowered the 1- or 2-GPCs.Table 3Results of MR of SZ on circulating glycerophosphocholines (1- or 2-GPCs).Table 3MethodNLowerUpper*P*-*Value*SNPsBetaStd. Error95% CI95% CI1-palmitoleoylglycerophosphocholineInverse variance weighted60-0.0210.006−0.032−0.0090.0003MR Egger regression60−0.0320.026−0.0820.0190.2275MR Egger intercept600.0010.002−0.0030.0050.6696Weighted mode60−0.0490.020−0.088−0.0090.0188Weighted median60−0.0280.009−0.045−0.0110.00141-heptadecanoylglycerophosphocholineInverse variance weighted58−0.0190.007−0.033−0.0050.0094MR Egger regression580.0300.035−0.0370.0980.3836MR Egger intercept58−0.0040.003−0.0090.0010.1516Weighted mode580.0010.026−0.0500.0520.9675Weighted median58−0.0120.010−0.0330.0080.22981-oleoylglycerophosphocholineInverse variance weighted56−0.0170.005−0.027−0.0070.0006MR Egger regression56−0.0300.022−0.0730.0120.1694MR Egger intercept560.0010.002−0.0020.0040.5295Weighted mode56−0.0230.015−0.0520.0060.1314Weighted median56−0.0190.007−0.032−0.0050.00762-oleoylglycerophosphocholineInverse variance weighted57−0.0140.005−0.024−0.0040.0074MR Egger regression57−0.0160.024−0.0630.0310.5086MR Egger intercept570.0000.002−0.0030.0040.9233Weighted mode57−0.0060.015−0.0360.0240.7033Weighted median57−0.0110.007−0.0260.0030.11571-myristoylglycerophosphocholineInverse variance weighted59−0.0180.007−0.031−0.0050.0066MR Egger regression59−0.0120.030−0.0710.0470.6953MR Egger intercept590.0000.002−0.0050.0040.8347Weighted mode59−0.0240.021−0.0660.0180.2648Weighted median59−0.0200.009−0.039−0.0020.0332Fig. 2MR results of genetic liability to SZ on 15 1- or 2-GPCs.Fig. 2

The results for the IVW estimates of individual SNPs for all models and the table with the complete list of findings for the MR of SZ on the 15 1- or 2-GPC metabolites, including the null associations, are available in the Supplement.

4. Discussion {#s0090}
=============

As the prevalence of SZ ranges from 4 to 7 per 1000 persons worldwide \[[@bb0115]\], both it and EOC are rare enough that there are few epidemiologic studies examining SZ as a risk factor for EOC. Those that have examined the influence of SZ on EOC have observed mixed findings. Comparing the incidence rate ratio (IRR) of EOC among those with and without SZ, a null but decreased risk for EOC has been reported (IRR 0.98; 95% confidence interval (CI) not specifically provided, but included 1) \[[@bb0120]\]. A large retrospective study in Sweden of 59,233 patients with SZ reported a null but increased risk for EOC (standardized incidence ratio, SIR, 1.13; 95% CI 0.95, −1.34) among schizophrenics after diagnosis, but a decreased risk for EOC prior to diagnosis (SIR 0.48; 95% CI 0.35, −0.65) \[[@bb0125]\]. These previous reported associations between SZ and EOC could reflect residual confounding, reverse causation, or measurement error.

A major strength of our investigation is that we leveraged large GWAS to examine these two rare diseases. Our approach optimized power to find associations. A weakness of our study is that we were not able to assess the strength of our MR instruments (F-statistics), due to missing effect-allele frequencies in the Ripke et al. \[[@bb0075]\] GWAS. However, this is balanced out by the advantage of the two-sample MR design: weak instruments bias causal associations towards the null in two-sample MR. Thus, if our SZ instruments were weak, we likely would not have observed the causal associations we did, as our findings would have been attenuated to the null. Although the MR of SZ on overall EOC was statistically well powered, our analysis of SZ on the EOC subtypes may have been unpowered due to the small number of cases. Thus, we cannot rule out the possibility that SZ is associated with mucinous, clear cell, and/or endometrioid carcinomas, as it was with overall EOC and high-grade serous carcinoma, the most common of the subtypes.

Aberrant choline metabolism is a feature of malignant transformation in breast and ovarian cancer cell lines, where it is marked by a change from low phosphocholine (PCho) and high 1- or 2-GPC levels to high PCho and low 1- or 2-GPC levels \[[@bb0050],[@bb0130],[@bb0135]\]. Aberrant choline metabolism has also been noted clinically for breast cancer patients, with higher 1- or 2-GPC levels being implicated in better prognosis \[[@bb0140]\]. In studies of schizophrenics, high choline concentrations have been observed in patients prior to antipsychotic treatment \[[@bb0145]\], pointing to perturbation of choline metabolism being independent from antipsychotic treatment and not a result of it. Moreover, GPCs, specifically, have been observed to be statistically lower in patients compared to controls in certain brain regions (antipsychotic use did not appear to be the cause) \[[@bb0150]\]. Here, we observed that SZ was associated with lower levels of several circulating 1- or 2-GPC metabolites and that SZ conferred a weak but notable increased risk for EOC.

Regarding SZ conferring an increased risk for EOC, we considered the possibility that our findings were influenced by psychoses secondary to anti-*N*-methyl-[d]{.smallcaps}-aspartate receptor (anti-NMDAR) encephalitis, which is associated with underlying ovarian teratomas \[[@bb0155]\]. In order for this to have induced bias into the present study, the original GWAS of SZ would need to have suffered from substantial misclassification bias; i.e., mistaking cases of anti-NMDAR psychosis for SZ. Since ovarian teratomas are rare and affect only women, it is unlikely the Ripke et al. \[[@bb0075]\] GWAS contained enough instances of this error for their associations to have been remarkably influenced. Thus, the results of the present study are unlikely to be explained by this phenomenon.

Ideally, we would have tested whether these SZ-associated 1- or 2-GPC metabolites caused EOC, but we did not have appropriate genetic instruments for this purpose. Instead, we postulate that disturbed choline metabolism may explain the causal association between SZ and EOC. It is also possible that something else may underlie the connection between the two conditions. For instance, Brown (2016) proposed that SZ may involve cell transformation, similar to that of early stage cancer initiation or attenuated tumorigenesis \[[@bb0160]\] -- but without taking on a complete tumor phenotype. This is a provocative hypothesis that fits with our observations but may also, if true, reflect other early features of cancer, perhaps immune rather than metabolic. Another possibility is that changes in choline metabolism in SZ perturb the one‑carbon cycle. While free choline is primarily used in phospholipid synthesis, excess choline serves as a source of one‑carbon units for methylation; choline can directly re-methylate homocysteine to contribute to methionine formation and homeostasis \[[@bb0165]\]. Thus, perhaps SZ-induced aberrant choline metabolism mimics the "cholinic phenotype" observed in EOC and/or contributes to it, maybe via perturbation of the one‑carbon cycle.

Minimally, our results highlight the possibility that something about SZ imparts risk for developing EOC. Understanding this risk has implications for the biology of both diseases and could aid efforts at earlier detection of EOC, especially if the biological process perturbed in the two conditions also occurs in the absence of SZ. Investigating alterations in choline metabolism is a starting point to focus future investigation.
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